GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays 6d ago GSK The Fly GSK Pharma put volume heavy and directionally bearish 9d ago GSK The Fly GSK price target lowered to 1,440 GBp from 1,550 GBp at JPMorgan
share comment s (49) recommended for you about glaxf stock symbol last price % chg 1d 5d 1m 6m 1y 5y 10y market cap pe yield rev growth (yoy) short interest prev. close compare to peers more on glaxf related stocks symbol last price % chg gsk gsk - - glaxf glaxf - - 1d 5d ...
GSK trades at a discount to both pharma and consumer peers despite paying out a higher dividend yield. If executed well, the company could see a meaningful boost to its share price, which has been stagnant for years.
History and development of the company GlaxoSmithKline plc, and its subsidiary and associated undertakings, constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. GlaxoSmithKline has its ...
(b) the minimum price which may be paid for each Ordinary share is 25p; (c) the maximum price which may be paid for each Ordinary share shall be the higher of (i) an amount equal to 5% above the average market value for the company's Ordinary shares for the five business days ...
has popped up on plenty of radar screens following some bold, unexpected moves. Investors will finally get the consumer healthcare spinoff they've been asking for through a recently formedjoint venturewithPfizer(PFE0.41%). The British pharma giant alsodived backinto the lucrative oncology space wi...
is a pharmaceutical company. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes, and mental health, and it also has a portfolio of vaccines. Operating in more than 115 countries, GSK is also engaged in the consumer healthcare business in oral health,...
Consumer business gained share overall across the full year. Reported growth was impacted, though, by a weaker performance in Europe, particularly in the second half, when we saw a much tougher competitive environment. We have responded but these plans will take though Q1 to make a full...
The transaction with Novartis really was about delivering scale in Consumer and an opportunity to transform the margin structure of that business, alongside maintenance of a very competitive growth rate. Over the next five years, we believe we can build something very special there. The Vaccine ...
© AP LexSince becoming chief executive a year ago Bernard Looney has tried hard to decarbonise BP. But the oil company’s share price has trailed its rivals in Europe andfull-year resultson Tuesday did nothing to dispel the gloom. ...